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Background: Dyslipidemia due to high total cholesterol, LDL-cholesterol, triglycerides, or low HDL-cholesterol is an
important risk factor for coronary heart disease (CHD). Both SIRT1 and PUFAs can influence the expression of genes
for nuclear receptors and transcription factors related to lipid metabolism such as LXRα, LXRβ, PPARα, SREBP-1c.
Methods: A total of 707 Japanese males and 723 females were randomly selected from the participants who
visited a medical center for routine medical check-ups. We analyzed the combined effects of the genotype/
haplotype of the SIRT1 gene and dietary n-6/n-3 PUFA intake ratio on the determination of serum lipid levels.
Results: We found that the SIRT1 gene marked with haplotype 2 was associated with decreased serum
LDL-cholesterol and increased HDL-cholesterol levels. In addition, the associations between the SIRT1 haplotype 2
and decreased LDL-C and increased HDL-C levels were only observed in the low n-6/n-3 PUFA intake ratio group,
but not in the high n-6/n-3 PUFA intake ratio group.
Conclusions: Our findings indicate that the combination of genetic variation in the SIRT1 gene and dietary n-6 and/or
n-3 PUFA intake influence the determination of inter-individual variations of serum levels of LDL-C and HDL-C.
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Dyslipidemia due to high total cholesterol, low density lipo-
protein (LDL)-cholesterol, triglycerides, or low high density
lipoprotein (HDL)-cholesterol is an important risk factor
for coronary heart disease (CHD) [1,2]. Data from family
and twin studies suggest that genetic variations account for
40-60% of the inter-individual variations in plasma lipid
levels [2,3]. In addition to rare mutations that cause familial
dyslipidemia, common genetic variants are considered to
significantly contribute to the heritability of plasma lipid
levels. For example, genome-wide association studies
(GWAS) have reported a growing number of new loci in-
volved in lipid metabolism [4,5]. However, loci identified* Correspondence: kobayasi@u-shizuoka-ken.ac.jp
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reproduction in any medium, provided the orthrough GWAS may not fully explain the inter-individual
variation in plasma lipid levels.
Sirtuin 1 (SIRT1) belongs to the sirtuin protein family of
nicotinamide adenine dinucleotide (NAD+)-dependent
histone deacetylases conserved in evolution from bacteria
to humans [6,7]. Human have seven sirtuin family mem-
bers, SIRT1-SIRT7, which exhibit with different cellular
locations, enzyme activities, target substrates and tissue-
specificity. Of these, SIRT1 has been most extensively
studied. SIRT1 is a nuclear protein and promotes chroma-
tin silencing and transcriptional repression through histone
deacetylation. In addition, more than a dozen non-histone
proteins serve as substrates for SIRT1. SIRT1 controls nu-
merous physiological processes and protects cells against
stress. A number of studies have shown that SIRT1 ortho-
logs are important mediators of the extension of life span
observed from yeast to mammals following calorie res-
triction. During energy crises such as calorie restriction,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the study subjects
Male Female P-value
n 707 723
Age (years) 53.8 ± 5.2 53.0 ± 5.1 0.075
BMI (kg/m2) 23.5 ± 2.9 22.2 ± 3.1 <0.0001
Total Cholesterol (mg/dl) 209.9 ± 31.4 217.7 ± 31.4 <0.0001
LDL-Cholesterol (mg/dl) 130.4 ± 29.8 131.9 ± 30.0 0.38
HDL-Cholesterol (mg/dl) 57.0 ± 16.3 71.5 ± 17.1 <0.0001
Triglyceride (mg/dl) 137.8 ± 102.5 86.8 ± 45.8 <0.0001*
glucose (mg/dl) 99.5 ± 15.4 92.7 ± 10.9 <0.0001*
HbA1c (%) 5.3 ± 0.59 5.1 ± 0.44 <0.0001
Smokers (%) 42.5 8.4 <0.0001
Dietary intakes
Energy (kcal/day) 2106.5 ± 567.0 1615.5 ± 414.9 <0.0001
Total fat (%energy) 25.9 ± 6.0 28.2 ± 5.7 <0.0001
Carbohydrate (%energy) 57.1 ± 7.8 56.0 ± 7.0 0.012
SFA (%energy) 6.5 ± 1.8 7.6 ± 2.0 <0.0001
PUFA (%energy) 6.7 ± 1.7 7.0 ± 1.6 0.0019
n-6 PUFA (%energy) 5.4 ± 1.5 5.7 ± 1.4 0.0004
n-3 PUFA (%energy) 1.5 ± 0.49 1.5 ± 0.44 0.42
Alcohol (g/day) 28.7 ± 31.6 6.5 ± 14.6 <0.0001
BMI body mass index, HbA1c hemoglobin A1c, SFA saturated fatty acid, PUFA
polyunsaturated fatty acid.
Data are expressed as mean ± SD or percentage.
P-values were calculated by t-test or χ2 test.
The subject numbers whose data for LDL-Cholesterol, HbA1c, and dietary
intake available are 1430, 1408, and 1248, respectively.
*Statistical tests for triglyceride and glucose levels were calculated on log-
transformed values.
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Transgenic mice overexpressing SIRT1 have beneficial cal-
orie restriction-like phenotypes, while down-regulation of
SIRT1 accelerates the aging phenotype in mice [8].
Furthermore, SIRT1 also has an important function in
lipid and glucose metabolism, due to deacetylation of a
number of nuclear receptors and transcription factors re-
lated to lipid and glucose metabolism such as peroxisome-
proliferator activated receptor (PPAR)α, PPARγ, peroxisome
proliferator-activated receptor gamma coactivator 1-α
(PGC1-α), liver X receptor (LXR)α, LXRβ, forkhead box O
(FOXO), AMP-activated protein kinase (AMPK) and sterol
response element-binding protein-1c (SREBP-1c) [6-11].
Thus, SIRT1 is associated with lipid metabolism, and va-
riations of the SIRT1 gene might affect the determination
of inter-individual variations of plasma lipid levels.
Fatty acids are no longer just sources of energy, but also
fine modulators of cellular signaling and metabolism [12].
There is growing evidence of health benefits of consuming
certain types of fats including n-6 and n-3 polyunsaturated
fatty acids (PUFAs)[12,13], which are essential fatty acids
that are not synthesized de novo by mammals. Several
studies have shown that dietary intake of n-6 PUFAs, such
as linoleic acid found in vegetable oils, may reduce CHD
risk by beneficial effects on serum total cholesterol, LDL
cholesterol, and insulin sensitivity [14], while n-3 PUFA
derived from fish has also been shown to decrease serum
triglyceride and increase HDL-cholesterol, which is asso-
ciated with more efficient reverse cholesterol transport
and a reduced risk of CHD [15,16]. It is also reported that
n-3 PUFA have anti-inflammatory effects [16]. However,
the cellular mechanisms underling the beneficial effects of
n-6 and n-3 PUFA on lipid profile and CHD prevention
are not completely understood. Recently, n-6 and n-3
PUFAs were shown to be critical for modulation of expres-
sion in several nuclear receptors and transcription factors,
including LXRα, LXRβ, PPARα, SREBP-1c, hepatocyte nu-
clear factor (HNF)-4α, and nuclear factor-κB (NFκB) [17].
The majority of these genes play key roles in lipid metabo-
lism, and their expression is also modulated by SIRT1
[6-11]. Furthermore, it was reported that calorie restric-
tion and dietary n-3 PUFA intake induce the similar bene-
ficial effects such as anti-inflammation, preventing obesity
and increasing expression insulin sensitivity in mice [18].
Recently, it was shown that the anti-inflammatory effect
of n-3 PUFAs might be mediated through activation of
AMPK/SIRT1 pathways; because of n-3 PUFAs increased
expression, phosphorylation and activity of AMPK in ma-
crophages, which further leaded to SIRT1 over-expression
[19]. These data indicate the possibility that dietary n-3
PUFAs intake modify the SIRT1 activity in vivo.
In the present study, we investigated whether the com-
mon variations in the SIRT1 gene are potential contribu-
tors to inter-individual variations in serum lipid levels.Furthermore, we analyzed the interaction of the common
SIRT1 variants and dietary n-3 and n-6 PUFAs intake on
determination of serum lipid levels.
Results
Table 1 shows demographic and biochemical characteris-
tics, and dietary intake of our subjects. There was a signifi-
cant difference in these data between male and female. As
such, we analyzed the data separately in male and female.
We examined the relationships between the genotypes/
haplotypes of the three single nucleotide polymorphisms
(SNPs) (rs7069102, rs2273773, rs3818292) in the SIRT1
gene and metabolic phenotypes such as levels of fasting
serum total cholesterol, LDL-cholesterol, HDL-cholesterol,
triglycerides, glucose, hemoglobin A1c (HbA1c), and body
mass index (BMI). These three SNPs were in linkage dis-
equilibrium (LD) with each other (|D’| > 0.87), and we
constructed a haplotype using these three SNPs. There
were three common haplotypes with frequencies of >16%,
which accounted for 98% of all chromosomes in our sub-
jects (see Additional file 1: Table S1, and Table S2).
In males, significant associations were observed between
LDL-cholesterol level and all three SNPs or haplotype 2,
Table 2 Relationships between genotypes/haplotypes of the SIRT1 gene and metabolic phenotypes
Genotype Total-Cholesterol LDL-Cholesterol HDL-Cholesterol Triglycerides* Glucose* HbA1c BMI**
n (mg/dl) n (mg/dl) n (mg/dl) n (mg/dl) n (mg/dl) n (%) n (kg/m2)
Male
rs7069102 CC 487 208.9 ± 31.4 482 129.4 ± 29.1 487 57.5 ± 16.7 487 135.2 ± 105.4 487 99.7 ± 15.7 484 5.27 ± 0.60 487 23.5 ± 2.8
(intron 4) CG 207 212.7 ± 31.4 203 133.5 ± 31.0 207 55.5 ± 15.3 207 146.0 ± 97.3 207 99.2 ± 14.8 206 5.29 ± 0.58 207 23.4 ± 2.9
GG 13 203.8 ± 31.8 13 122.7 ± 34.3 13 60.6 ± 13.7 13 100.8 ± 55.5 13 93.5 ± 12.1 13 5.33 ± 0.61 13 24.1 ± 7.1
P value 0.067 0.010 0.42 0.017 0.31 0.46 0.55
rs2273773 TT 315 212.4 ± 33.2 311 134.4 ± 30.6 315 55.3 ± 15.7 315 136.4 ± 103.1 315 99.2 ± 14.8 313 5.29 ± 0.58 315 23.4 ± 2.9
(exon 5) TC 294 208.8 ± 29.6 290 127.1 ± 28.5 294 58.1 ± 16.4 294 140.2 ± 106.8 294 99.8 ± 16.9 293 5.25 ± 0.64 294 23.5 ± 2.9
CC 98 207.8 ± 30.4 97 127.7 ± 30.0 98 58.9 ± 17.5 98 134.7 ± 87.3 98 99.5 ± 12.2 97 5.31 ± 0.47 98 23.7 ± 2.8
P value 0.32 0.024 0.054 0.86 0.71 0.81 0.40
rs3818292 AA 313 212.4 ± 33.4 309 134.3 ± 30.6 313 55.4 ± 15.6 313 136.1 ± 103.7 313 99.4 ± 14.8 311 5.29 ± 0.59 313 23.4 ± 2.9
(intron 5) AG 297 208.0 ± 29.4 293 127.3 ± 28.4 297 57.9 ± 16.4 297 140.6 ± 106.0 297 99.7 ± 16.9 296 5.26 ± 0.64 297 23.5 ± 3.0
GG 97 207.8 ± 30.7 96 127.7 ± 30.2 97 59.1 ± 17.8 97 134.4 ± 87.7 97 99.0 ± 12.0 96 5.31 ± 0.46 97 23.7 ± 2.7
P value 0.27 0.024 0.10 0.70 0.75 0.85 0.34
haplotype 1 + 515 210.6 ± 32.4 510 131.6 ± 30.1 515 56.6 ± 16.2 515 135.7 ± 102.2 515 99.9 ± 16.5 513 5.28 ± 0.63 515 23.5 ± 2.8
(C-T-A) - 192 208.1 ± 28.6 188 127.2 ± 28.7 192 58.0 ±16.6 192 143.2 ± 103.5 192 98.2 ± 11.6 190 5.28 ± 0.48 192 23.5 ± 3.2
P value 0.53 0.150 0.24 0.21 0.34 0.59 0.86
haplotype 2 + 384 208.0 ± 29.7 379 127.4 ± 28.8 384 58.1 ± 16.7 384 139.8 ± 102.8 384 99.7 ± 16.0 382 5.27 ± 0.60 384 23.5 ± 2.7
(C-C-G) - 323 212.2 ± 33.2 319 134.1 ± 30.5 323 55.6 ± 15.7 323 135.3 ± 102.3 323 99.2 ± 14.7 321 5.29 ± 0.58 323 23.5 ± 3.2
P value 0.17 0.011 0.049 0.47 0.60 0.68 0.14
haplotype 3 + 213 212.5 ± 31.6 209 133.2 ± 31.3 213 55.5 ± 14.9 231 144.4 ± 97.1 213 99.1 ± 14.8 212 5.30 ± 0.59 213 22.4 ± 3.2
(G-T-A) - 494 208.8 ± 31.3 489 129.2 ± 29.1 494 57.6 ± 16.8 494 134.9 ± 104.8 494 99.6 ± 15.6 491 5.27 ± 0.59 494 23.5 ± 2.8
P value 0.069 0.055 0.31 0.053 0.57 0.37 0.51
Female
rs7069102 CC 504 217.7 ± 31.9 492 131.7 ± 30.9 504 71.6 ± 17.2 504 85.7 ± 43.2 504 92.9 ± 11.3 493 5.14 ± 0.45 504 22.2 ± 3.2
(intron 4) CG 198 217.9 ± 30.2 190 132.0 ± 28.0 198 71.8 ± 17.0 198 87.8 ± 50.2 198 92.0 ± 9.0 192 5.16 ± 0.40 198 22.1 ± 2.9
GG 21 215.0 ± 31.1 20 134.4 ± 26.3 21 63.6 ± 15.9 21 102.8 ± 59.6 21 94.3 ± 17.7 20 5.11 ± 0.44 21 22.7 ± 2.8
P value 0.63 0.82 0.12 0.13 0.75 0.20 0.50
rs2273773 TT 310 218.6 ± 32.0 300 134.0 ±30.8 310 70.0 ± 16.8 310 89.9 ± 49.3 310 93.3 ± 12.9 301 5.17 ± 0.50 310 22.2 ± 3.0
(exon 5) TC 320 215.6 ± 31.0 315 129.0 ± 29.7 320 72.5 ± 17.2 320 83.5 ± 40.8 320 91.8 ± 8.9 316 5.12 ± 0.37 320 22.1 ± 3.1
CC 93 221.7 ± 30.4 87 135.0 ± 27.3 93 72.8 ± 17.7 93 87.6 ± 49.4 93 93.4 ±10.0 88 5.15 ± 0.44 93 22.6 ± 3.4





















Table 2 Relationships between genotypes/haplotypes of the SIRT1 gene and metabolic phenotypes (Continued)
rs3818292 AA 303 219.1 ± 31.9 294 134.4 ± 30.4 303 69.8 ± 16.9 303 90.3 ± 49.1 303 93.5 ± 13.0 295 5.17 ± 0.50 303 22.2 ± 3.0
(intron 5) AG 309 214.9 ± 30.8 305 128.7 ± 30.1 309 72.4 ± 17.0 309 83.3 ± 41.4 309 91.7 ± 9.1 305 5.12 ± 0.37 309 22.1 ± 3.2
GG 111 221.8 ± 30.9 103 133.8 ± 27.9 111 73.4 ± 17.8 111 86.8 ± 47.6 111 93.2 ± 9.2 105 5.13 ± 0.42 111 22.5 ± 3.30
P value 0.11 0.061 0.047 0.17 0.090 0.94 0.83
haplotype 1 + 515 216.9 ± 31.8 504 131.7 ± 31.1 515 70.8 ± 16.8 515 86.6 ± 44.2 515 92.7 ± 11.1 505 5.14 ± 0.45 515 22.1 ± 3.1
(C-T-A) - 208 219.7 ± 30.1 198 132.2 ± 26.9 208 73.2 ± 17.7 208 87.2 ± 49.6 208 92.7 ± 10.5 200 5.14 ± 0.41 208 22.3 ± 3.1
P value 0.47 0.77 0.045 0.65 0.70 0.43 0.88
haplotype 2 + 408 216.9 ± 31.0 397 130.1 ± 29.4 408 72.6 ± 17.2 408 84.5 ± 43.0 408 92.1 ± 9.1 399 5.13 ± 0.38 408 22.2 ± 3.2
(C-C-G) - 315 218.7 ± 31.9 305 134.1 ± 30.6 315 69.9 ± 16.9 315 89.7 ± 49.0 315 93.4 ± 12.9 306 5.16 ± 0.50 315 22.2 ± 3.0
P value 0.27 0.039 0.065 0.16 0.088 0.85 0.95
haplotype 3 + 216 217.5 ± 30.4 208 132.4 ± 28.0 216 71.0 ± 17.1 216 88.9 ± 51.5 216 92.2 ± 10.2 209 5.15 ± 0.41 216 22.2 ± 2.9
(G-T-A) - 507 217.8 ± 31.8 494 131.6 ± 30.8 507 71.7 ± 17.1 507 85.8 ± 43.1 507 92.9 ± 11.2 496 5.14 ± 0.45 507 22.2 ± 3.2
P value 0.96 0.67 0.47 0.22 0.92 0.29 0.72
Values are shown as mean ± SD.
P-values were calculated by multiple linear regression analyses incorporating age, BMI, current smoking and alcohol intake as covariates.
*Statistical tests for glucose and TG levels were calculated on log-transformed values.
**P-values for BMI were calculated by multiple linear regression analyses incorporating age, current smoking and alcohol intake as covariates.





















Table 3 The combined effects of SIRT1 haplotype and n-6/n-3 PUFA intake ratio on serum LDL-C and HDL-C levels
Male Female
Low n6/n3 intake group
(<3.79)
High n6/n3 intake group
(≧3.79)
Low n6/n3 intake group
(<3.93)
High n6/n3 intake group
(≧3.93)
n (mg/dl) n (mg/dl) n (mg/dl) n (mg/dl)
LDL-Cholesterol
Haplotype 1 (+) 221 133.5 ± 31.1 232 131.1 ± 29.3 215 133.6 ± 30.5 213 131.2 ± 31.3
Haplotype 1 (−) 88 127.0 ± 29.8 74 129.4 ± 28.6 93 131.3 ± 26.2 84 131.1 ± 28.1
P-value 0.13 0.68 0.53 0.87
Haplotype 2 (+) 179 128.0 ± 30.5 149 129.4 ± 28.6 187 129.7 ± 27.6 163 130.2 ± 30.6
Haplotype 2 (−) 130 136.6 ± 30.7 157 131.9 ± 29.7 121 137.9 ± 31.0 134 132.4 ± 30.1
P-value 0.0089 0.28 0.0085 0.68
Haplotype 3 (+) 82 136.8 ± 30.2 95 131.5 ± 31.6 82 131.1 ± 25.1 98 134.0 ± 30.2
Haplotype 3 (−) 227 129.8 ± 30.9 211 130.3 ± 28.1 226 133.6 ± 30.6 199 129.8 ± 30.5
P-value 0.033 0.56 0.99 0.49
HDL-Cholesterol
Haplotype 1 (+) 223 55.7 ± 16.8 234 56.8 ± 15.9 218 72.1 ± 17.2 220 69.0 ± 16.7
Haplotype 1 (−) 89 58.3 ± 16.7 77 57.0 ± 16.0 96 76.9 ± 17.8 91 69.5 ± 17.4
P-value 0.16 0.72 0.022 0.92
Haplotype 2 (+) 181 57.6 ± 17.1 152 57.4 ± 16.4 190 75.5 ± 17.4 170 69.4 ± 17.1
Haplotype 2 (−) 131 54.8 ± 16.4 159 56.4 ± 15.4 124 70.5 ± 17.4 141 68.9 ± 16.7
P-value 0.079 0.27 0.032 0.83
Haplotype 3 (+) 84 53.8 ± 14.9 97 56.6 ± 15.0 84 71.3 ± 17.1 104 69.6 ± 17.7
Haplotype 3 (−) 228 57.4 ± 17.4 214 57.0 ± 16.3 230 74.4 ± 17.6 207 68.9 ± 16.5
P-value 0.14 0.90 0.15 0.72
Values are shown as mean ± SD.
P-values were calculated by multiple linear regression analyses incorporating age, BMI, current smoking and alcohol intake as covariates.
Statistically significant P-values (P < 0.05) are indicated by bold.
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females, significant associations were observed between
LDL-cholesterol level and haplotype 2, and between HDL-
cholesterol levels and SNP (rs3818292) or haplotype 1.
The other metabolic traits including serum total choles-
terol, glucose, HbA1c levels, and BMI were not associated
with the genotype/haplotype of the SIRT1 gene (Table 2).
The carriers of haplotype 2 had lower serum LDL-C
and higher HDL-C levels than for the non-carriers of
haplotype 2, although in females the relationship be-
tween HDL-C levels and haplotype 2 was not statistically
significant (P = 0.065). These data indicate that haplotype
2 is a beneficial haplotype associated with decreased
LDL-cholesterol and increased HDL-cholesterol levels.
Next, to examine whether dietary n-6 and n-3 PUFA in-
take modulates the association between SIRT1 haplotypes
and LDL-C and/or HDL-C levels, we classified subjects
into two subgroups based on the population median of
dietary n-6/n-3 PUFA intake ratio (3.79 for males, 3.93 for
females). Significant associations between SIRT1 haplotype
2 and LDL-C and/or HDL-C levels were observed in only
the group with a low n-6/n-3 PUFA intake ratio, but werenot observed in the group with a high n-6/n-3 PUFA in-
take ratio (Table 3). In the group with a low n-6/n-3 PUFA
intake ratio, the association between haplotype 3 and
LDL-C levels in male (P = 0.033), and that between hap-
lotype 1 and HDL-C levels in female were also observed
(P = 0.022).
These findings indicate that the combination of genetic
variations in the SIRT1 gene and dietary n-6 and/or n-3
PUFA intake influence the determination of inter-
individual variations of serum levels of LDL-C and HDL-C.
Discussion
Plasma levels of high LDL-C and low HDL-C are con-
sidered major determinants of susceptibility to CHD in
the general population. The determination of plasma
lipid levels is controlled by multiple pathways and influ-
enced by complex interactions between many different
genes and environmental factors such as diet intake.
In the present study, we found that the combination
between the SIRT1 gene marked with haplotype 2 and
low n-6/n-3 PUFA intake ratio was related to beneficial
effects on serum lipid profile, a decreased LDL-C and an
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SIRT1 and PUFAs can influence the expression of genes
for nuclear receptors and transcription factors related to
lipid metabolism including LXRα, LXRβ, PPARα,
SREBP-1c [9-11,17]. Recently, it was reported that n-3
PUFAs activate AMPK/SIRT1 pathways in macrophages
[19]. These data indicate the possibility that the activity
or function of SIRT1 might be modified by dietary n-3
PUFAs intake. In addition, it remains possible that the
activity of SIRT1 marked with haplotype 2 is more easily
increased by n-3 PUFA intake without haplotype 2. At
present, we have no direct evidence that the activity of
SIRT1 was influenced by dietary n-3 PUFA intake, and
the SIRT1 gene marked with haplotype 2 in this study
caused alterations in the activity and/or function of
SIRT1 deacetylase.
Genetic variants of the SIRT1 gene have been shown
to be associated with human diabetes and obesity-
related phenotypes in several previous studies [20-22],
while only a few genetic association studies for the
SIRT1 gene and lipid metabolism have been reported
[23]. Almost all genetic variants detected in the SIRT1
gene were synonymous, only a few variants with possible
functional changes were reported in the promoter region
[24]. The three SNPs that we analyzed in this study are
also non-functional variants. And we could not detect
associations between genotype/haplotype of the SIRT1
gene and diabetes and obesity-related phenotypes in-
cluding serum glucose levels, HbA1c, and BMI in this
study (Table 2). However, it remains possible that the
SIRT1 gene marked with haplotype 2 might exist in link-
age disequilibrium with other new functional variants.
Further in vivo and in vitro studies are needed to as-
sess the role for dietary n-3 or n-6 PUFA intake and
genetic variation marked with haplotype 2 in the SIRT1
gene on changes in SIRT1 expression or function.
The lower saturated fat (meat) and higher n-3-PUFA
(fish) in the Japanese diet was suggested to contribute to
the lower prevalence of hypercholesterolemia and lower
risk of CHD [25]. Furthermore, the beneficial SIRT1 va-
riant marked with haplotype 2 is rather common in the
Japanese population (the frequency of haplotype 2 is 0.33).
Future studies are required to ascertain whether the com-
bination between the SIRT1 gene marked with haplotype 2
and low n-6/n-3 PUFA intake ratio can produce beneficial
effects on serum lipid profile in other populations contain-
ing young people, children, or other people with different
dietary habits. Prospective cohort studies are also required
to determine the interactions between genetic variations of
the SIRT1 gene and dietary PUFA on serum lipid profile. It
is important to determine the potential for interactions be-
tween genetic and modifiable environmental factors such
as dietary nutrient intake to establish a preventive method
for common diseases such as dyslipidemia and CHD.Conclusion
We found that the genotype/haplotype of the SIRT1 gene
is associated with serum LDL-C and HDL-C levels, and
that the variant marked with haplotype 2 is associated with
decreased LDL-cholesterol and increased HDL-cholesterol
levels. In addition, the associations between the SIRT1
haplotype 2 and decreased LDL-C and/or increased HDL-
C levels were only observed in the low n-6/n-3 PUFA in-
take ratio group, but not in the high n-6/n-3 PUFA intake
ratio group. These findings indicate that the combination
of genetic variations in the SIRT1 gene and dietary n-6
and/or n-3 PUFA intake can influence the determination
of inter-individual variations of serum levels of LDL-C and
HDL-C. An understanding of the interactions of genetic
and environmental factors on the prevalence of dyslipide-
mia is useful for prediction and prevention of CHD, as




A total of 707 Japanese males and 723 females were
randomly selected from participants who visited a medical
center near the University of Shizuoka for routine medical
check-ups. Subjects were all Japanese, and ranged from
45–65 years (mean age, 53.8 ± 5.2 males, 53.0 ± 5.1
females). People taking medication for dyslipidemia
and/or diabetes were excluded from the study subjects.
After overnight fasting, blood samples were collected
from each subject. Written informed consent was
obtained from all subjects and this study was approved
by the Ethics Committee of the University of Shizuoka.
DNA analysis
Genomic DNA was isolated from peripheral leucocytes by
the phenol extraction method. We analyzed the genotypes
and haplotypes of three tag SNPs (rs7069102 [intron 4],
rs2273773 [exon 5, Leu27Leu], rs3818292 [intron 5]) in
the SIRT1 gene, which were selected from the HapMap
database (http://hapmap.ncbi.nlm.nih.gov/index.html.en),
based on their minor allele frequencies (MAF) in the
Japanese population and previous reports describing the
SIRT1 polymorphism [20,23]. The SIRT1 gene is localized
to chromosome region 10q21.3 with 9 exons. To date, ap-
proximately 100 common SNPs (MAF≧ 0.05) have been
on the dbSNP database (http://www.ncbi.nlm.nih.gov/
snp?term). The majority of SNPs exist in intron or un-
translated regions.
The genotypes of these three SNPs were determined for
each subject using the PCR-restriction fragment length
polymorphism method. The haplotypes and their frequen-
cies were estimated by the maximum-likelihood method
with an expectation-maximization-based algorithm using
the SNPAlyze program (Dynacom, Tokyo, Japan).
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Dietary intake was assessed using a brief-type self-admi-
nistered diet history questionnaire (BDHQ). The BDHQ
was developed based on the self-administered diet history
questionnaire (DHQ), which had been validated using
three different standard methods for dietary assessment
[26,27]. The BDHQ were designed to obtain dietary habits
for the previous month from validating dietary intake for
58 food and beverage items which are commonly con-
sumed in general Japan populations [26,27]. With respect
to n-3 and n-6 PUFA, the majority food sources are
α-linolenic acid (vegetable oil), EPA (fish and shellfish),
DHA (fish and shellfish) and linoleic acid (vegetable oil),
arachidonic acid (fish, organ meats and egg), respectively.
Intake of fat, carbohydrate, protein, and fatty acids was
expressed as percentages of the total non-alcohol energy
intake. Dietary data were available for 1248 subjects
(87.3%) in this study.
Statistical analyses
The relationships between genotypes/haplotypes of the
three SNPs of the SIRT1 gene and metabolic parameters
including serum lipid and glucose levels were analyzed by
multiple linear regression analyses incorporating age,
BMI, alcohol intake, and smoking status as covariates.
Statistical analyses were performed using the JMP 9 soft-
ware package (SAS Institute, Cary, NC, USA). The coeffi-
cients of linkage disequilibrium (LD) value (|D’| and r2)
among three SNPs were calculated by using the SNPAlyze
program (Dynacom, Tokyo, Japan).
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Additional file 1: Table1. The pair wise linkage disequilibrium (LD)
values of |D'| (upper) and r2 (lower). Table 2. Estimated SIRT1 haplotypes
and frequencies in the Japanese population.
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